Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy ...

Kepler Cheuvreux initiated coverage of Danish medtech company Coloplast with a “buy” rating and a target price of DKK482.

There’s something fishy about Coloplast’s latest megadeal—literally. The Danish medtech announced (PDF) plans on Friday to acquire Kerecis, which uses fish skin as the basis of its wound care products ...

COPENHAGEN, July 7 (Reuters) - Coloplast (COLOb.CO), opens new tab has agreed to buy Iceland-based Kerecis, a biologic wound care firm that uses fish skin to develop tissue-transplant products, for up ...

Coloplast (CLPBY) faces operational challenges, with four consecutive top-line misses and reduced growth expectations, but retains a strong core franchise. CLPBY's CEO search remains unresolved, and ...

The new intermittent catheter Luja™ addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole ...

Coloplast is now rated a cautious 'Buy,' as its valuation has become more reasonable after a significant price correction. Coloplast continues to deliver solid organic growth, boasts a wide economic ...

Though foreign-exchange headwinds have nagged at Coloplast COLO B, underlying demand remains robust and revenue growth remains on track to meet our full-year projections. We’re holding steady on our ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Coloplast A/S (COLO-B.CO), a medical devices manufacturer, reported Tuesday a loss in its second quarter, compared to prior year's profit, mainly hurt by a hefty impairment ...